Activating two somatostatin receptors enhances amyloid beta breakdown and improves memory in models of Alzheimer’s disease.

On July 2, the U.S. Food and Drug Administration (FDA) approved a new drug for treating Alzheimer’s disease. Donanemab, or Kisunla, is the third drug approved to target one of the causes of ...

New research shows that aging blood can accelerate Alzheimer’s-like changes in the brain, while younger blood may offer ...

In a recent study posted to the bioRxiv preprint* server, researchers in Sweden investigated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein amyloid as a potential ...

Solving the structure of an amyloid protein gives new insight into limb-girdle muscular dystrophy type 3 (LGMD D3) and functional protein aggregation. LGMD D3 is a rare disease characterized by slow ...

As the investigators in that trial concluded, “The long-term implications of these findings are unknown and may be assessed in longer-term follow-up and in the phase 3 study (Clarity-AD).” The ...

A recent study led by a team of researchers at The Johns Hopkins University School of Medicine examining aging mice has provided what is believed to be the first evidence that amyloid beta ...